Scinai Immunotherapeutics (SCNI) Receivables - Other (2021 - 2025)

Scinai Immunotherapeutics has disclosed Receivables - Other across 5 years of filings, most recently posting $87000.0 for Q4 2025.

• In Q4 2025, Receivables - Other fell 15.53% year-over-year to $87000.0; the TTM figure through Dec 2025 stood at $87000.0 (down 15.53% YoY), while the FY2025 annual figure was $87000.0, down 15.53% from the prior year.
• Receivables - Other came in at $87000.0 for Q4 2025 at Scinai Immunotherapeutics, down from $103000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $5.8 million in Q2 2023 to a low of -$123000.0 in Q1 2022.
• Average Receivables - Other over 5 years is $653900.0, with a median of $99500.0 recorded in 2022.
• The largest YoY upside for Receivables - Other was 74.8% in 2023 against a maximum downside of 185.42% in 2023.
• Over 5 years, Receivables - Other stood at $326000.0 in 2021, then sank by 52.45% to $155000.0 in 2022, then advanced by 14.84% to $178000.0 in 2023, then plunged by 42.13% to $103000.0 in 2024, then declined by 15.53% to $87000.0 in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $87000.0 in Q4 2025, $103000.0 in Q4 2024, and $178000.0 in Q4 2023.